| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | - | - | - | - | 0 | 0 | 0 | 0 | 2 | 0 |
| Total Expenses - EUR | - | - | - | - | 53.858 | 1.020 | 0 | 0 | 166 | 0 |
| Gross Profit/Loss - EUR | - | - | - | - | -53.858 | -1.020 | 0 | 0 | -164 | 0 |
| Net Profit/Loss - EUR | - | - | - | - | -53.858 | -1.020 | 0 | 0 | -164 | 0 |
| Employees | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Grocanna Pharma S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | - | - | - | - | 11.008 | 10.232 | 10.005 | 10.037 | 9.842 | 9.787 |
| Inventories | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | - | 47 | 120 | 118 | 118 | 118 | 117 |
| Cash | - | - | - | - | 10.961 | 10.112 | 9.888 | 9.918 | 9.725 | 9.670 |
| Shareholders Funds | - | - | - | - | -43.838 | -44.027 | -43.051 | -43.184 | -43.217 | -42.975 |
| Social Capital | - | - | - | - | 10.020 | 9.830 | 9.612 | 9.642 | 9.613 | 9.559 |
| Debts | - | - | - | - | 54.846 | 54.259 | 53.056 | 53.221 | 53.059 | 52.763 |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "128 - 128" | |||||||||
| CAEN Financial Year |
128
|
|||||||||
Comments - Grocanna Pharma S.r.l.